Technical Analysis for PROK - ProKidney Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Inside Day | Range Contraction | -17.14% | |
| Wide Bands | Range Expansion | -17.14% | |
| Up 3 Days in a Row | Strength | -17.14% | |
| MACD Bullish Signal Line Cross | Bullish | -12.12% | |
| Wide Bands | Range Expansion | -12.12% | |
| Wide Bands | Range Expansion | -6.20% |
| Alert | Time |
|---|---|
| 20 DMA Support | 2 days ago |
| Down 2 ATRs | 2 days ago |
| Fell Below 10 DMA | 2 days ago |
| 10 DMA Support | 2 days ago |
| Down 10% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/03/2024
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.51 |
| 52 Week Low | 1.12 |
| Average Volume | 847,366 |
| 200-Day Moving Average | 2.88 |
| 50-Day Moving Average | 2.50 |
| 20-Day Moving Average | 3.35 |
| 10-Day Moving Average | 3.75 |
| Average True Range | 0.45 |
| RSI (14) | 54.34 |
| ADX | 44.82 |
| +DI | 29.66 |
| -DI | 17.38 |
| Chandelier Exit (Long, 3 ATRs) | 3.08 |
| Chandelier Exit (Short, 3 ATRs) | 3.39 |
| Upper Bollinger Bands | 4.67 |
| Lower Bollinger Band | 2.04 |
| Percent B (%b) | 0.55 |
| BandWidth | 78.25 |
| MACD Line | 0.39 |
| MACD Signal Line | 0.41 |
| MACD Histogram | -0.022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.96 | ||||
| Resistance 3 (R3) | 5.06 | 4.66 | 4.71 | ||
| Resistance 2 (R2) | 4.66 | 4.28 | 4.61 | 4.63 | |
| Resistance 1 (R1) | 4.07 | 4.05 | 3.87 | 3.97 | 4.55 |
| Pivot Point | 3.67 | 3.67 | 3.57 | 3.62 | 3.67 |
| Support 1 (S1) | 3.08 | 3.29 | 2.88 | 2.99 | 2.41 |
| Support 2 (S2) | 2.68 | 3.06 | 2.63 | 2.33 | |
| Support 3 (S3) | 2.09 | 2.68 | 2.25 | ||
| Support 4 (S4) | 2.00 |
